Franson PharmAdvisors Joins B&D Consulting Health & Life Sciences Group
B&D Consulting, a division of Baker & Daniels LLP, announced today that Franson PharmAdvisors LLC, led by international regulatory expert Tim Franson, M.D., has merged its consulting practice with the firm's health and life sciences group. Dr. Franson will serve as a Senior Vice President and lead the B&D Consulting regulatory affairs practice.
"We are delighted to have Tim join our team of professionals who focus on serving the health and life sciences sector," commented Dave Zook, Chair of B&D Consulting. "Many B&D Consulting clients will appreciate his global experience in moving innovation to market and addressing regulatory requirements once the product is available to patients. This business combination reflects our commitment to develop deep, sector-focused consulting teams built around integrated disciplines that anticipate and respond to client needs."
"I'm very enthused about being able to build upon and expand our current portfolio of services for the biopharma industry by joining such a strong and diverse practice," said Dr. Franson. "We now have the unique collective capabilities for pre- and post-approval regulatory, reimbursement and issues management expertise integrated into one team."
Dr. Franson's arrival adds clinical regulatory expertise to B&D Consulting's existing policy, reimbursement and strategic communication services.
"We are thrilled to have Tim on our team. A number of our clients have already taken advantage of the expertise Tim brings to our integrated line of services," said Ed Dougherty, leader of B&D Consulting's health and life sciences practice.
Dr. Franson is a physician and pharmacist by training. Prior to launching Franson PharmAdvisors LLC, he served in a series of senior leadership positions with Eli Lilly and Company, most recently retiring from the position of Vice President of Global Regulatory Affairs and Drug Safety. Dr. Franson also served as a principal representative of the pharmaceutical industry through the Prescription Drug User Fee Act negotiations and reauthorizations. His consulting practice has provided professional services for drug biologics development management.